OPTICAL FIBRES

Protected optical fiber package

PROTECTED OPTICAL FIBER PACKAGE

Benzotriazole UV absorbers having enhanced durability

INHIBITORS OF DIACYLGLYCEROL O-ACYLTRANSFERASE TYPE 1 ENZYME

Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. 2. The compound of having formula (I) claim 1 , or a pharmaceutically acceptable salt claim 1 , prodrug claim 1 , salt of a prodrug claim 1 , or a combination thereof claim 1 , wherein X is —(CRR)—C(O)—Xor C(O)—X.3. The compound of having formula (I) claim 1 , or a pharmaceutically acceptable salt claim 1 , prodrug claim 1 , salt of a prodrug claim 1 , or a combination thereof claim 1 , wherein X is —(CRR)—C(O)—X claim 1 , and Q is phenyl claim 1 , optionally further substituted with 1 claim 1 , 2 claim 1 , or 3 T.4. The compound of having formula (I) claim 1 , or a pharmaceutically acceptable salt claim 1 , prodrug claim 1 , salt of a prodrug claim 1 , or a combination thereof claim 1 , wherein{'sup': k', 'm', '2, 'sub': 'u', 'X is —(CRR)—C(O)—XQ is phenyl, optionally further substituted with 1, 2 or 3 T:{'sup': 'a', 'A is phenyl, optionally further substituted with 1, 2, 3, 4, or 5 substituents represented by R: and'}r and s are 2.5. The compound of having formula (I) claim 1 , or a pharmaceutically acceptable salt claim 1 , prodrug claim 1 , salt of a prodrug claim 1 , or a combination thereof claim 1 , wherein{'sup': k', 'm', '2, 'sub': 'u', 'X is —(CRR)—C(O)—XQ is phenyl, optionally further substituted with 1, 2, or 3 T;r and s are 2, and{'sup': 'a', 'A is a 5- or 6-membered monocyclic heteroaryl, optionally further substituted with 1, 2, 3, 4, or 5 substituents represented by R.'}6. The compound of having formula (I) claim 1 , or a pharmaceutically acceptable salt claim 1 , prodrug claim 1 , salt of a prodrug claim 1 , or a combination thereof claim 1 , wherein{'sup': k', 'm', '2, 'sub': 'u', 'X is —(CRR)—C(O)—X,'}Q is phenyl, optionally further substituted with 1, 2, or 3 T;r and s are 2, andA is formula (a).7. The compound of having formula (I) claim 1 , or a pharmaceutically acceptable salt claim 1 , prodrug claim 1 , salt of a prodrug ...

Resource sharing to reduce implementation costs in a multicore processor

A processor may include several processor cores, each including a respective higher-level cache; a lower-level cache including several tag units each including several controllers, where each controller corresponds to a respective cache bank configured to store data, and where the controllers are concurrently operable to access their respective cache banks; and an interconnect network configured to convey data between the cores and the lower-level cache. The controllers in a given tag unit may share access to a resource that may include one or more of an interconnect egress port coupled to the interconnect network, an interconnect ingress port coupled to the interconnect network, a test controller, or a data storage structure.

System and method for automatic recognition and labeling of anatomical structures and vessels in medical imaging scans

A system and method for recognizing and labeling anatomical structures in an image includes creating a list of objects such that one or more objects on the list appear before a target object and setting the image as a context for a first object on the list. The first object is detected and labeled by subtracting a background of the image. A local context is set for a next object on the list using the first object. The next object is detected and labeled by registration using the local context. Setting a local context and detecting and labeling the next object are repeated until the target object is detected and labeled. Labeling of the target object is refined using region growing.

Increasing Power Efficiency Of Turbo Mode Operation In A Processor

In one embodiment, a processor has multiple cores to execute threads. The processor further includes a power control logic to enable entry into a turbo mode based on a comparison between a threshold and value of a counter that stores a count of core power and performance combinations that identify turbo mode requests of at least one of the threads. In this way, turbo mode may be entered at a utilization level of the processor that provides for high power efficiency. Other embodiments are described and claimed. 1. A processor comprising:a plurality of cores each including a plurality of front end units, at least one execution unit and at least one cache memory; anda power control unit (PCU) including a first storage to store a plurality of performance state indicators each to indicate whether a corresponding thread has requested a first performance state and a second storage to store a plurality of core power state indicators each to indicate whether the corresponding thread has requested a first core power state, wherein the PCU is to control entry into a turbo mode based on information in the first and second storages.2. The processor of claim 1 , wherein the PCU includes a plurality of turbo mode counters each associated with a thread executing on the processor.3. The processor of claim 2 , wherein the PCU is to update the turbo mode counter for a first thread to indicate a turbo mode request if the performance state indicator and the core power state indicator for the first thread are both of a first state.4. The processor of claim 3 , wherein the PCU is to update the turbo mode counter in a first direction according to a first weight if the performance state indicator and the core power state indicator are both of the first state claim 3 , and otherwise to update the turbo mode counter in a second direction according to a second weight claim 3 , the second weight greater than the first weight.5. The processor of claim 4 , wherein the first and second weights are ...

sGC STIMULATORS

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: 3. A compound according to claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein ring B is phenyl.4. A compound according to claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein each Jis independently selected from halogen claim 2 , a Calkyl claim 2 , —ORand —OR.5. A compound according to claim 4 , or a pharmaceutically acceptable salt thereof claim 4 , wherein n is 2 and each Jis a halogen atom.7. A compound according to claim 6 , or a pharmaceutically acceptable salt thereof claim 6 , wherein Jis a Calkyl chain claim 6 , optionally substituted by up to 5 instances of fluorine.8. A compound according to claim 6 , or a pharmaceutically acceptable salt thereof claim 6 , wherein Ris H or Calkyl optionally and independently substituted with 0-5 occurrences of R; and Ris halo in each instance.9. A compound according to claim 6 , wherein Ris —CF.10. A compound according to claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , wherein q is 0.11. A compound according to claim 7 , or a pharmaceutically acceptable salt thereof claim 7 , wherein each instance of Jis hydrogen.13. A compound according to claim 12 , or a pharmaceutically acceptable salt thereof claim 12 , wherein Ris H or Calkyl optionally and independently substituted with 0-5 occurrences of R; and Ris halo in each instance.14. A compound according to claim 12 , wherein Ris —CF.15. A compound according to claim 12 , or a pharmaceutically acceptable salt thereof claim 12 , wherein q is 0.16. A ...

2-BENZYL, 3-(PYRIMIDIN-2-YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS

Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. 1. A compound depicted in Table I or a pharmaceutically acceptable salt thereof.2. A method of treating a disease claim 1 , health condition or disorder in a subject claim 1 , comprising administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , to the subject in need of the treatment claim 1 , wherein the disease claim 1 , health condition or disorder is selected from: disorders related to high blood pressure and decreased coronary blood flow; resistant hypertension; diabetic hypertension; congestive heart failure; diastolic or sistolic dysfunction; coronary insufficiency; arrhythmias;', 'thromboembolic disorders and ischemias; stable or unstable angina pectoris;', 'peripheral arterial disease, peripheral occlusive arterial disease;', 'pulmonary/respiratory conditions such as pulmonary hypertension, pulmonary arterial hypertension, and associated pulmonary vascular remodeling, pulmonary hypertonia, primary pulmonary hypertension, secondary pulmonary hypertension, familial pulmonary hypertension, sporadic pulmonary hypertension, pre-capillary pulmonary hypertension, idiopathic pulmonary hypertension, thrombotic pulmonary arteriopathy, plexogenic pulmonary arteriopathy;', 'pulmonary hypertension associated with or related to: left ventricular dysfunction, hypoxemia, mitral valve disease, constrictive pericarditis, aortic stenosis, cardiomyopathy, mediastinal fibrosis, pulmonary fibrosis, anomalous pulmonary venous drainage, pulmonary venooclusive disease, pulmonary vasculitis, collagen vascular disease, congenital heart disease, pulmonary venous hypertension, interstitial lung disease, sleep-disordered breathing, sleep apnea, alveolar hypoventilation ...

sGC STIMULATORS

Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 167-. (canceled)69. The compound of claim 68 , or a pharmaceutically acceptable salt thereof claim 68 , wherein n is an integer selected from 1 or 2 and wherein each Jis independently selected from halogen claim 68 , a Calkyl or —OR.70. (canceled)71. The compound of claim 69 , or a pharmaceutically acceptable salt thereof claim 69 , wherein each Jis independently selected from fluoro or chloro.7286-. (canceled)87. The compound of claim 68 , or a pharmaceutically acceptable salt thereof claim 68 , wherein ring B is phenyl.88. The compound of claim 68 , or a pharmaceutically acceptable salt thereof claim 68 , wherein ring B is a 6-membered heteroaryl ring or a thiophene ring.89. The compound of claim 88 , or a pharmaceutically acceptable salt thereof claim 88 , wherein ring B is a pyridyl ring.90. The compound of claim 88 , or a pharmaceutically acceptable salt thereof claim 88 , wherein ring B is a pyrimidinyl ring.91. (canceled)92. The compound of claim 89 , or a pharmaceutically acceptable salt thereof claim 89 , wherein Jis fluoro claim 89 , chloro or is absent.93. (canceled)94. The compound of claim 68 , or a pharmaceutically acceptable salt thereof claim 68 , wherein Jis hydrogen.95. The compound of claim 68 , or a pharmaceutically acceptable salt thereof claim 68 , wherein ring C is a monocyclic 5-membered heteroaryl ring containing 1 or 2 ring heteroatoms selected from N claim 68 , O or S.96. The compound of claim 95 , or a pharmaceutically acceptable salt thereof claim 95 , wherein ring C is an oxazole or isoxazole ring.97. The compound of claim 96 , or a pharmaceutically acceptable salt thereof claim 96 , wherein ring C is unsubstituted.98113-. (canceled)114. The compound of claim 68 , or a ...

PYRAZOLE DERIVATIVES AS SGC STIMULATORS

Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and one or more excipients.3. A method of treating a disease claim 1 , health condition or disorder in a subject in need of treatment claim 1 , comprising administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , or a pharmaceutical composition of claim 1 , to the subject in need of treatment claim 1 , wherein the disease claim 1 , health condition or disorder is selected from:disorders related to high blood pressure and decreased coronary blood flow; increased acute and chronic coronary blood pressure; arterial hypertension; vascular disorder resulting from cardiac and renal complications; vascular disorders resulting from heart disease, stroke, cerebral ischemia or renal failure; resistant hypertension; diabetic hypertension; essential hypertension; secondary hypertension; gestational hypertension; pre-eclampsia; portal hypertension; myocardial infarction;heart failure, HFPEF, HFREF; acute and chronic HF; more specific forms of HF: acute decompensated HF, right ventricular failure, left ventricular failure, total HF, ischemic cardiomyopathy, dilatated cardiomyopathy, congenital heart defects, HF with valvular defects, mitral valve stenosis, mitral valve insufficiency, aortic valve stenosis, aortic valve insufficiency, tricuspid stenosis, tricuspic insufficiency, pulmonary valve stenosis, pulmonary valve insufficiency, combined valvular defects; diabetic heart failure; alcoholic cardiomyopathy or storage cardiomyopathies; diastolic HF, systolic HF; acute phases of an existing chronic HF (worsening HF); diastolic or systolic dysfunction; ...

sGC STIMULATORS

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I:

INCREASING POWER EFFICIENCY OF TURBO MODE OPERATION IN A PROCESSOR

In one embodiment, a processor has multiple cores to execute threads. The processor further includes a power control logic to enable entry into a turbo mode based on a comparison between a threshold and value of a counter that stores a count of core power and performance combinations that identify turbo mode requests of at least one of the threads. In this way, turbo mode may be entered at a utilization level of the processor that provides for high power efficiency. Other embodiments are described and claimed. 1. A processor comprising:a plurality of cores each including at least one execution unit; anda power controller including a plurality of turbo mode counters each associated with a thread executing on the processor, each of the turbo mode counters to be updated in a first direction when a combined state of a performance state and a core power state requested by the corresponding thread is of a first combined state and to be updated in a second direction when the combined state is of any other combined state, wherein the power controller includes circuitry configured to control entry into a turbo mode based at least in part on a comparison of a value of at least one of the plurality of turbo mode counters to a trigger threshold.2. The processor of claim 1 , wherein the first combined state comprises a turbo mode request.3. The processor of claim 1 , further comprising a first storage to store a plurality of performance state indicators each to indicate whether a corresponding thread has requested a first performance state and a second storage to store a plurality of core power state indicators each to indicate whether the corresponding thread has requested a first core power state.4. The processor of claim 3 , wherein the power controller further includes circuitry configured to update the turbo mode counter for a first thread to indicate the first combined state if the performance state indicator and the core power state indicator for the first thread are both ...

Sgc stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).

sGC STIMULATORS

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: 2. The method according to claim 1 , wherein the disease claim 1 , health condition or disorder is selected from Alzheimer's disease claim 1 , amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) claim 1 , Down syndrome claim 1 , dementia claim 1 , vascular dementia claim 1 , vascular cognitive impairment claim 1 , Binswanger's dementia (subcortical arteriosclerotic encephalopathy) claim 1 , Cerebral Autosomal-Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL or CADASIL syndrome) claim 1 , frontotemporal lobar degeneration or dementia claim 1 , HIV-associated dementia claim 1 , Lewy body dementia claim 1 , pre-senile dementia (mild cognitive impairment claim 1 , MCI) claim 1 , glaucoma claim 1 , Huntington's diseases (or chorea claim 1 , HD) claim 1 , multiple sclerosis (MS) claim 1 , multiple system atrophy (MSA) claim 1 , Parkinson's disease claim 1 , Parkinsonism Plus claim 1 , spinocerebellar ataxias claim 1 , Steel-Richardson-Olszewski disease (progressive supranuclear palsy) claim 1 , attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD).3. The method according to claim 1 , wherein the disease claim 1 , health condition or disorder is neuropathic pain.4. The method according to claim 1 , wherein the disease claim 1 , health condition or disorder is selected from a psychiatric claim 1 , mental claim 1 , mood or affective disorder selected from a bipolar disorder claim 1 , schizophrenia claim 1 , general psychosis claim 1 , drug- ...

Co-Polymer Soil Subgrade Binders

This invention is in the field of road construction as it relates to improving the quality and lifetime of asphalt roads and pavement surfaces. The invention relates to methods and compositions utilizing co-polymers in combination with soil to form improved subgrade soil binder compositions for supporting asphalt roads and pavement surfaces.

sGC STIMULATORS

Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 1169-. (canceled)171. The method of claim 170 , wherein the disease claim 170 , health condition or disorder is a peripheral claim 170 , pulmonary claim 170 , hepatic claim 170 , kidney claim 170 , cardiac or cerebral vascular/endothelial disorder or condition claim 170 , or a disease otherwise related to circulation selected from: increased acute and chronic coronary blood pressure; arterial hypertension; vascular disorder resulting from cardiac and renal complications claim 170 , heart disease claim 170 , stroke claim 170 , cerebral ischemia claim 170 , renal failure; resistant hypertension claim 170 , diabetic hypertension; congestive heart failure; diastolic or systolic dysfunction; coronary insufficiency; arrhythmias; reduction of ventricular preload; cardiac hypertrophy; heart failure/cardiorenal syndrome; portal hypertension; endothelial dysfunction or injury; myocardial infarction; stroke; transient ischemic attacks (TIAs); obstructive thromboanginitis; stable or unstable angina pectoris; coronary spasms claim 170 , variant angina claim 170 , Prinzmetal's angina; restenosis as a result of thrombolysis therapies and thrombogenic disorders.172. The method of claim 170 , wherein the disease claim 170 , health condition or disorder is a peripheral vascular/endothelial disorder or condition or a disease otherwise related to circulation selected from: peripheral arterial disease claim 170 , peripheral occlusive arterial disease; peripheral vascular disease; hypertonias; Raynaud's syndrome or phenomenon; critical limb ischemia; vasculitis; peripheral embolism; intermittent claudication; vaso-occlusive crisis; Duchenne and Becker muscular dystrophies; microcirculation abnormalities; and vascular leakage or ...

sGC STIMULATORS

Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 167-. (canceled)69. The compound of claim 68 , or a pharmaceutically acceptable salt thereof claim 68 , wherein n is an integer selected from 1 or 2 and wherein each Jis independently selected from halogen claim 68 , a Calkyl or —OR.70. (canceled)71. The compound of claim 69 , or a pharmaceutically acceptable salt thereof claim 69 , wherein each Jis independently selected from fluoro or chloro.7286-. (canceled)87. The compound of claim 68 , or a pharmaceutically acceptable salt thereof claim 68 , wherein ring B is phenyl.88. The compound of claim 68 , or a pharmaceutically acceptable salt thereof claim 68 , wherein ring B is a 6-membered heteroaryl ring or a thiophene ring.89. The compound of claim 88 , or a pharmaceutically acceptable salt thereof claim 88 , wherein ring B is a pyridyl ring.90. The compound of claim 88 , or a pharmaceutically acceptable salt thereof claim 88 , wherein ring B is a pyrimidinyl ring.91. (canceled)92. The compound of claim 89 , or a pharmaceutically acceptable salt thereof claim 89 , wherein Jis fluoro claim 89 , chloro or is absent.93. (canceled)94. The compound of claim 68 , or a pharmaceutically acceptable salt thereof claim 68 , wherein Jis hydrogen.95. The compound of claim 68 , or a pharmaceutically acceptable salt thereof claim 68 , wherein ring C is a monocyclic 5-membered heteroaryl ring containing 1 or 2 ring heteroatoms selected from N claim 68 , O or S.96. The compound of claim 95 , or a pharmaceutically acceptable salt thereof claim 95 , wherein ring C is an oxazole or isoxazole ring.97. The compound of claim 96 , or a pharmaceutically acceptable salt thereof claim 96 , wherein ring C is unsubstituted.98113-. (canceled)114. The compound of claim 68 , or a ...

sGC STIMULATORS

The present patent application discloses at least the compounds according to Formula I′ shown below, or pharmaceutically acceptable salts thereof, 8. The compound of represented by Formula IIA or Formula IIB claim 7 , or a pharmaceutically acceptable salt thereof.918-. (canceled)19. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein W is absent.2021-. (canceled)23. The compound according to claim 22 , or a pharmaceutically acceptable salt thereof claim 22 , wherein ring B is phenyl or a 5 to 6-membered heteroaryl ring containing 1 or 2 ring heteroatoms selected from N claim 22 , O or S.24. (canceled)25. The compound according to claim 23 , or a pharmaceutically acceptable salt thereof claim 23 , wherein n is an integer selected from 1 claim 23 , 2 or 3 claim 23 , and wherein each Jis independently selected from halogen claim 23 , a Caliphatic or —OR.2640-. (canceled)41. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein:{'sup': C1', '7', '7', '7', '7', '7', '7', '7', '2', '7', '7', '7', '7', '8, 'sub': 1-6', '2', '2', '2', '2', '1-6, 'Ris selected from hydrogen, halogen, oxo, —CN, Caliphatic, —OR, —COR, —C(O)OR, —C(O)N(R), —N(R)C(O)R, —N(R), —SR, —S(O)R, —SOR, —SON(R); wherein each said Caliphatic is optionally and independently substituted with up to 6 instances of fluoro and up to 2 instances of ORor oxo; and'}{'sup': 'C2', 'Ris selected from hydrogen or halogen.'}42. (canceled)4449-. (canceled)5156-. (canceled)57. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein Jis J claim 1 , —N(R) claim 1 , —N(R)SONHR claim 1 , —N(R)SONHCO(O)OR claim 1 , or —N(R)SONHC(O)R.5866-. (canceled)6884-. (canceled)86. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and one or more excipients.87. A method of treating a disease claim 1 , health condition or disorder in a subject ...

sGC STIMULATORS

Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 1169.-. (canceled)171. The method of claim 170 , further comprising administering an effective amount of one or more additional therapeutic agents to the subject.172. The method of claim 171 , wherein the one or more additional therapeutic agents are selected from anti-diabetic agents claim 171 , SGLT-2 inhibitors claim 171 , neprilysin inhibitors claim 171 , angiotensin receptor blockers (ARB) claim 171 , angiotensin converting enzyme (ACE) inhibitors claim 171 , mineralocorticoid receptor (MR) antagonists claim 171 , and endothelin receptor antagonists (ERAs).173. The method of claim 172 , wherein the one or more additional therapeutic agents are anti-diabetic agents selected from insulin and insulin mimetics claim 172 , sulfonylureas claim 172 , biguanides claim 172 , α-glucosidase inhibitors claim 172 , thiazolidinone compounds claim 172 , insulin sensitizers claim 172 , insulin secretagogues claim 172 , GLP-1 receptor agonists claim 172 , incretin mimetics claim 172 , amylin analogues claim 172 , glucose lowering agents claim 172 , dipeptidyl peptidase IV (DPP4) inhibitors claim 172 , AVE-0277 claim 172 , Alum-GAD claim 172 , BHT-3021 claim 172 , IBC-VS01 claim 172 , and other drugs in development for the treatment of diabetes.174. The method of claim 173 , wherein the sulfonylureas are selected from glyburide claim 173 , glybenclamide claim 173 , glipizide claim 173 , gliclazide claim 173 , gliquidone claim 173 , glimepiride claim 173 , meglinatide claim 173 , tolbutamide claim 173 , chlorpropamide claim 173 , acetohexamide claim 173 , and tolazimide; the α-glucosidase inhibitors are selected from acarbose claim 173 , epalrestat claim 173 , voglibose claim 173 , and miglitol; the thiazolidinone compounds are ...

sGC STIMULATORS

The present patent application discloses at least the compounds according to Formula l shown below, or pharmaceutically acceptable salts thereof, wherein ring,, J, J,, X, X, J, R, and W are as defined herein. These compounds are useful as simulators of soluble sGC. 1103-. (canceled)1051. The compound of claim , or a pharmaceutically acceptable salt thereof , wherein each Jis independently selected from halogen , N(R) , and OR.1081. The compound of claim , or a pharmaceutically acceptable salt thereof , wherein each Jis independently selected from methyl , trifluoromethyl , chloro , fluoro , N(R) , or —OR.1111. The compound according to claim , wherein Ris a Calkyl , optionally substituted with up to 6 instances of fluoro.114. The compound according to claim 113 , wherein ring E is a heterocyclic ring containing one nitrogen ring atom and wherein at least one instance of Jis oxo.115. The compound of claim 114 , wherein one Jis oxo and two other instances of Jare independently selected from —(Y)—R.116. The compound of claim 115 , wherein each —(Y)—Ris independently selected from a Calkyl; —C(O)O—R claim 115 , —NH(CO)—ORand —C(O)NH—R.117. The compound of claim 116 , wherein Ris hydrogen claim 116 , a Calkyl claim 116 , or a Ccycloalkyl ring.118. The compound of claim 107 , wherein Ris selected from the group consisting of hydrogen claim 107 , Calkyl claim 107 , and a Calkyl-R; and Ris selected from the group consisting of hydrogen and Calkyl; wherein each of said Calkyl and the Calkyl portion of the Calkyl-Rmoiety claim 107 , is optionally and independently substituted with up to 5 instances of R.1191. A pharmaceutical composition comprising the compound of claim claim 107 , or a pharmaceutically acceptable salt thereof claim 107 , and at least one pharmaceutically acceptable excipient.1201. A method of treating a disease claim 107 , health condition or disorder in a subject in need of treatment claim 107 , comprising administering a therapeutically effective amount of ...

PYRAZOLE DERIVATIVES AS SGC STIMULATORS

Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and one or more excipients.3. A method of treating a disease claim 1 , health condition or disorder in a subject in need of treatment claim 1 , comprising administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , to the subject in need of treatment claim 1 , wherein the disease claim 1 , health condition or disorder is selected from:disorders related to high blood pressure and decreased coronary blood flow; increased acute and chronic coronary blood pressure; arterial hypertension; vascular disorder resulting from cardiac and renal complications; vascular disorders resulting from heart disease, stroke, cerebral ischemia or renal failure; resistant hypertension; diabetic hypertension; essential hypertension; secondary hypertension; gestational hypertension; pre-eclampsia; portal hypertension; myocardial infarction;heart failure, HFPEF, HFREF; acute and chronic HF; more specific forms of HF: acute decompensated HF, right ventricular failure, left ventricular failure, total HF, ischemic cardiomyopathy, dilated cardiomyopathy, congenital heart defects, HF with valve defects, mitral valve stenosis, mitral valve insufficiency, aortic valve stenosis, aortic valve insufficiency, tricuspid stenosis, tricuspic insufficiency, pulmonary valve stenosis, pulmonary valve insufficiency, combined valvular defects; diabetic heart failure; alcoholic cardiomyopathy or storage cardiomyopathies; diastolic HF, systolic HF; acute phases of an existing chronic HF (worsening HF); diastolic or systolic dysfunction; coronary insufficiency; arrhythmias; reduction of ...

sGC STIMULATORS

Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. 174-. (canceled)76. The method of claim 75 , wherein the disease claim 75 , health condition or disorder is(a) a peripheral or cardiac vascular disorder or health condition selected from:pulmonary hypertension, pulmonary arterial hypertension, and associated pulmonary vascular remodeling, localized pulmonary thrombosis, right heart hypertrophy, pulmonary hypertonia, primary pulmonary hypertension, secondary pulmonary hypertension, familial pulmonary hypertension, sporadic pulmonary hypertension, pre-capillary pulmonary hypertension, idiopathic pulmonary hypertension, thrombotic pulmonary artheriopathy, plexogenic pulmonary artheriopathy; pulmonary hypertension associated with or related to: left ventricular dysfunction, hypoxemia, mitral valve disease, constrictive pericarditis, aortic stenosis, cardiomyopathy, mediastinal fibrosis, pulmonary fibrosis, anomalous pulmonary venous drainage, pulmonary venooclusive disease, pulmonary vasculitis, collagen vascular disease, congenital heart disease, pulmonary venous hypertension, interstitial lung disease, sleep-disordered breathing, apnea, alveolar hypoventilation disorders, chronic exposure to high altitude, neonatal lung disease, alveolar-capillary dysplasia, sickle cell disease, other coagulation disorders, chronic thromboembolism, pulmonary embolism, connective tissue disease, lupus, schitosomiasis, sarcoidosis, chronic obstructive pulmonary disease, emphysema, chronic bronchitis, pulmonary capillary hemangiomatosis; histiocytosis X, lymphangiomatosis or compressed pulmonary vessels;(b) liver cirrhosis, or(c) a urogenital system disorder selected from renal fibrosis, renal failure resulting from chronic kidney diseases or insufficiency, erectile dysfunction or female sexual ...

RECLAIMING AND REUSING PRE-BOOT RESERVED MEMORY POST-BOOT

Described is a system where memory can be allocated for use by an adapter pre-boot and preserved for use post-boot. A BIOS can allocate for pre-boot hardware operations (e.g., graphics drivers, framebuffers, etc.) and mark this allocated memory as preserved. An indication of the allocated memory can be provided for an OS, such that post-boot, the OS can reclaim and reallocate this memory. 1. An apparatus , comprising:a processor; and allocate a portion of memory for use by circuitry during pre-boot of an operating system;', 'mark the portion of the memory as preserved; and', 'provide an indication of the portion of the memory for the operating system such that the portion of the memory can be reclaimed by the operating system during post-boot of the operating system., 'a memory storing instructions, which when executed by the processor, cause the processor to2. The apparatus of claim 1 , the instructions claim 1 , when executed by the processor claim 1 , cause the processor to allocate the portion of the memory for use by a graphics output protocol (GOP) framebuffer.3. The computing apparatus of claim 2 , the instructions claim 2 , when executed by the processor claim 2 , cause the processor to dynamically allocate the portion of memory based on the GOP framebuffer contents.4. The computing apparatus of claim 2 , the instructions claim 2 , when executed by the processor claim 2 , cause the processor to populate a graphics translation table (GTT) based on a memory address of the portion of memory.5. The computing apparatus of claim 2 , the instructions claim 2 , when executed by the processor claim 2 , cause the processor to provide a memory address of the portion of memory as the indication.6. The computing apparatus of claim 2 , the GOP framebuffer arranged to store video display data.7. The computing apparatus of claim 1 , the instructions claim 1 , when executed by the processor claim 1 , cause the processor to mark the portion of the memory as a preserved memory ...

PLATFORM INDEPENDENT ISA EMULATOR AS MIDDLEWARE

A hardware/software architecture cars include a high-level software stack on which a plurality of software applications are executing, an underlying hardware platform having a hardware platform type, and a middleware layer residing between the high-level software stack and the underlying hardware platform and configured to allow two or more of the plurality of software applications to interact with each other independent of the hardware platform type. 1. A hardware/software architecture , comprising:a high-level software stack on which a plurality of software applications are executing;an underlying hardware platform having a hardware platform type; anda middleware layer residing between the high-level software stack and the underlying hardware platform and configured to allow two or more of the plurality of software applications to interact with each other independent of the hardware platform type.2. The hardware/software architecture of claim 1 , further comprising at least one operating system (OS) in the high-level software stack.3. The hardware/software architecture of claim 1 , wherein the hardware platform type comprises an ARM instruction set architecture (ISA).4. The hardware/software architecture of claim 1 , wherein the middleware layer is further configured to provide interface options comprising new universal standard instruction sets.5. The hardware/software architecture of claim 1 , wherein the plurality of software applications comprises an ARM-based application claim 1 , and wherein the middleware layer is further configured to enable the ARM-based application to run on a different architecture.6. The hardware/software architecture of claim 1 , wherein the middleware layer is further configured to receive offloaded legacy instruction set architectures.7. The hardware/software architecture of claim 1 , wherein the middleware layer is further configured to receive offloaded low-performance instruction set architectures.8. The hardware/software ...

sGC STIMULATORS

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: 3. A compound according to claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein n is an integer selected from 1 or 2 and each Jis independently selected from halogen claim 2 , a Calkyl claim 2 , —ORor —OR.4. A compound according to claim 3 , or a pharmaceutically acceptable salt thereof claim 3 , wherein n is 1.515-. (canceled)16. A compound according to claim 2 , or a pharmaceutically acceptable salt thereof claim 2 , wherein ring B is phenyl.17. A compound according to claim 16 , or a pharmaceutically acceptable salt thereof claim 16 , wherein n is 1 or 2.18. A compound according to claim 17 , or a pharmaceutically acceptable salt thereof claim 17 , wherein a Jis ortho to the attachment of the methylene linker between ring B and the core of the molecule claim 17 , and the Jis halogen.1923-. (canceled)2528-. (canceled)30. A compound according to claim 29 , or a pharmaceutically acceptable salt thereof claim 29 , wherein Ris H claim 29 , NRR claim 29 , —C(O)NRR claim 29 , C(O)R claim 29 , —SOR claim 29 , —SR claim 29 , halo claim 29 , —OCF claim 29 , —CN claim 29 , hydroxyl claim 29 , Calkenyl optionally and independently substituted with 0-2 occurrences of R claim 29 , Calkynyl optionally and independently substituted with 0-2 occurrences of R; Calkyl optionally and independently substituted with 0-5 occurrences of R claim 29 , Calkoxy optionally and independently substituted with 0-3 occurrences of R claim 29 , phenyl optionally and independently substituted with 0-3 occurrences ...

PYRAZOLE DERIVATIVES AS SGC STIMULATORS

Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and one or more excipients.3. A method of treating a disease claim 1 , health condition or disorder in a subject in need of treatment claim 1 , comprising administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , to the subject in need of treatment claim 1 , wherein the disease claim 1 , health condition or disorder is selected from:disorders related to high blood pressure and decreased coronary blood flow; increased acute and chronic coronary blood pressure; arterial hypertension; vascular disorder resulting from cardiac and renal complications; vascular disorders resulting from heart disease, stroke, cerebral ischemia or renal failure; resistant hypertension;diabetic hypertension; essential hypertension; secondary hypertension; gestational hypertension; pre-eclampsia; portal hypertension; myocardial infarction;heart failure, HFPEF, HFREF; acute and chronic HF; more specific forms of HF: acute decompensated HF, right ventricular failure, left ventricular failure, total HF, ischemic cardiomyopathy, dilated cardiomyopathy, congenital heart defects, HF with valvular defects, mitral valve stenosis, mitral valve insufficiency, aortic valve stenosis, aortic valve insufficiency, tricuspid stenosis, tricuspic insufficiency, pulmonary valve stenosis, pulmonary valve insufficiency, combined valvular defects; diabetic heart failure; alcoholic cardiomyopathy or storage cardiomyopathies; diastolic HF, systolic HF; acute phases of an existing chronic HF (worsening HF); diastolic or systolic dysfunction; coronary insufficiency; arrhythmias; reduction of ...

sGC STIMULATORS

The present patent application discloses at least the compounds according to Formula I′ shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, ring F, J B , n, J D , o, R C1 , R C2 , W, J E , r, J F , s, Z 1 , Z 2 and Z 3 are as defined herein.

PYRAZOLE DERIVATIES AS SGC STIMULATORS

Compounds are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and one or more excipients.3. A method of treating a disease claim 1 , health condition or disorder in a subject in need of treatment claim 1 , comprising administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , to the subject in need of treatment claim 1 , wherein the disease claim 1 , health condition or disorder is selected from:disorders related to high blood pressure and decreased coronary blood flow; increased acute and chronic coronary blood pressure; arterial hypertension; vascular disorder resulting from cardiac and renal complications; vascular disorders resulting from heart disease, stroke, cerebral ischemia or renal failure; resistant hypertension; diabetic hypertension; essential hypertension; secondary hypertension; gestational hypertension; pre-eclampsia; portal hypertension; myocardial infarction;heart failure, HFPEF, HFREF; acute and chronic HF; more specific forms of HF: acute decompensated HF, right ventricular failure, left ventricular failure, total HF, ischemic cardiomyopathy, dilated cardiomyopathy, congenital heart defects, HF with valve defects, mitral valve stenosis, mitral valve insufficiency, aortic valve stenosis, aortic valve insufficiency, tricuspid stenosis, tricuspic insufficiency, pulmonary valve stenosis, pulmonary valve insufficiency, combined valvular defects; diabetic heart failure; alcoholic cardiomyopathy or storage cardiomyopathies; diastolic HF, systolic HF; acute phases of an existing chronic HF (worsening HF); diastolic or systolic dysfunction; coronary insufficiency; arrhythmias; reduction of ...

SGC STIMULATORS

The present patent application discloses at least the compounds according to Formula I shown below, or pharmaceutically acceptable salts thereof, 2. (canceled)4. (canceled)6. (canceled)7. (canceled)8. (canceled)10. (canceled)11. (canceled)12. The compound of any one of claim 9 , or a pharmaceutically acceptable salt thereof claim 9 , wherein each Jis independently selected from halogen claim 9 , a Caliphatic claim 9 , Chaloaliphatic claim 9 , —N(R) claim 9 , —N(R)COR claim 9 , —N(R)COOR claim 9 , —OR claim 9 , —N(R)SOR claim 9 , or an optionally substituted Ccycloaliphatic ring.13. (canceled)14. (canceled)15. (canceled)16. (canceled)17. (canceled)20. (canceled)21. (canceled)23. (canceled)24. The compound of claim 22 , or a pharmaceutically acceptable salt thereof claim 22 , wherein n is an integer selected from 1 to 3 and wherein each Jis independently selected from halogen claim 22 , a Caliphatic or —OR.25. The compound of claim 24 , or a pharmaceutically acceptable salt thereof claim 24 , wherein each Jis independently selected from halogen.2641-. (canceled)42. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein each Jis independently selected from halogen claim 1 , a Caliphatic claim 1 , a Chaloaliphatic —N(R) claim 1 , —N(R)C(O)R claim 1 , —N(R)C(O)OR claim 1 , —N(R)C(O)N(R) claim 1 , —SOR claim 1 , —SON(R) claim 1 , N(R)SOR claim 1 , —SR claim 1 , —ORor an optionally substituted Ccycloaliphatic ring.43. The compound of claim 42 , or a pharmaceutically acceptable salt thereof claim 42 , wherein each Jis independently selected from methyl claim 42 , trifluoromethyl claim 42 , chloro claim 42 , fluoro claim 42 , —N(R) claim 42 , —N(R)C(O)R claim 42 , —N(R)SORor —OR.4453-. (canceled)5557-. (canceled)60. (canceled)61. The compound according to claim 1 , wherein Ris hydrogen.62. The compound according to claim 1 , wherein Ris a Caliphatic claim 1 , optionally substituted with up to 6 instances of fluoro.6365-. (canceled)66. A ...

sGC STIMULATORS

Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. 2. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein ring B is phenyl.3. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein n is an integer selected from 1 to 3 and wherein each Jis independently selected from halogen claim 1 , a Caliphatic or —OR.4. The compound of claim 3 , or a pharmaceutically acceptable salt thereof claim 3 , wherein each Jis independently selected from halogen atoms.517-. (canceled)18. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein ring B is a 6-membered heteroaryl ring.1922-. (canceled)23. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein o is 0.24. The compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , wherein o is an integer selected between 1 and 3 and each Jis independently selected from halogen claim 1 , a Caliphatic claim 1 , —N(R) claim 1 , —N(R)C(O)R claim 1 , —N(R)C(O)OR claim 1 , —SOR claim 1 , —SON(R) claim 1 , —N(R)SOR claim 1 , —SR claim 1 , —ORor an optionally substituted Ccycloaliphatic ring.2530-. (canceled)31. The compound of claim 24 , or a pharmaceutically acceptable salt thereof claim 24 , wherein each Ris independently selected from a Calkyl or hydrogen and each Ris independently selected from hydrogen or Calkyl.3233-. (canceled)34. The compound of claim 24 , or a pharmaceutically acceptable salt thereof claim 24 , wherein o is 1 claim 24 , 2 or 3 and each Jis independently selected from methyl claim 24 , fluoro claim 24 , —N(R) claim 24 , —N(R)C(O)RD claim 24 , —N(R)C(O)OR claim 24 , —SOR claim 24 , —SON(R)or —N(R)SOR; wherein each Rand each Ris independently selected from hydrogen or methyl.35 ...

PHOSPHORUS PRODRUGS OF SGC STIMULATORS

The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof, wherein J, n, R, R, R, R, R, m and X as defined herein. 23-. (canceled)4. The compound according to claim 1 , wherein X is —P(O)(OH).5. The compound according to claim 1 , wherein X is —P(O)(OH)OM or —P(O)(O)(M); and M is selected from Na claim 1 , K or the monovalent cation of an organic amine.6. The compound according to claim 1 , wherein X is —P(O)(O)D; and D is selected from Ca claim 1 , Cs claim 1 , Zn claim 1 , Mg or the divalent cation of an organic amine.79-. (canceled)1213-. (canceled)14. The compound according to claim 1 , wherein n is 0 claim 1 , 1 or 2.1517-. (canceled)18. The compound according to claim 14 , wherein all instances of Jare fluoro claim 14 , or all instances of Jare chloro claim 14 , or some instances of Jare fluoro and some instances of Jare chloro.1929-. (canceled)30. The compound according to claim 1 , wherein both Rand Rare simultaneously Cfluoroalkyl or both Rand Rare simultaneously Cfluoroalkyl or both Rand Rare simultaneously trifluoromethyl.3138-. (canceled)39. The compound according to wherein m is 1.40. The compound according to wherein m is 0.4144-. (canceled)45. The compound according to claim 1 , wherein Ris selected from hydrogen claim 1 , chloro or fluoro.4648-. (canceled)49457. A compound according to claim claim 1 , wherein Ris fluoro.50. (canceled)51. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , and one or more excipients.52. A method of treating a disease claim 1 , health condition or disorder in a subject in need of treatment claim 1 , comprising administering a therapeutically effective amount of the compound of claim 1 , or a pharmaceutically acceptable salt thereof claim 1 , to the subject in need of treatment claim 1 , wherein the disease claim 1 , health condition or disorder is selected from:disorders ...

sGC STIMULATORS

Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 1169-. (canceled)172. A pharmaceutical composition comprising a compound of claim 171 , or a pharmaceutically acceptable salt thereof claim 171 , and one or more excipients.174. A method of treating a disease claim 171 , health condition or disorder in a subject in need of treatment claim 171 , comprising administering a therapeutically effective amount of the compound of claim 171 , or a pharmaceutically acceptable salt thereof claim 171 , to the subject in need of treatment claim 171 , wherein the disease claim 171 , health condition or disorder is selected from: disorders related to high blood pressure and decreased coronary blood flow; increased acute and chronic coronary blood pressure; arterial hypertension; vascular disorder resulting from cardiac and renal complications, heart disease, stroke, cerebral ischemia or renal failure; resistant hypertension; diabetic hypertension; congestive heart failure; diastolic or systolic dysfunction; coronary insufficiency; arrhythmias; reduction of ventricular preload; cardiac hypertrophy; heart failure/cardiorenal syndrome; portal hypertension; endothelial dysfunction or injury;', "thromboembolic disorders and ischemias; myocardial infarction; stroke; transient ischemic attacks (TIAs); obstructive thromboanginitis; stable or unstable angina pectoris; coronary spasms; variant angina; Prinzmetal's angina; restenosis resulting from thrombolysis therapies; thrombogenic disorders;", "Alzheimer's disease; Parkinson's disease; dementia; vascular cognitive impairment; cerebral vasospasm; traumatic brain injury;", "peripheral arterial disease; peripheral occlusive arterial disease; peripheral vascular disease; hypertonias; Raynaud's syndrome or phenomenon; critical limb ischemia ...

2-BENZYL, 3-(PYRIMIDIN-2-YL) SUBSTITUTED PYRAZOLES USEFUL AS SGC STIMULATORS

Compound of Table I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. 1. (canceled)2. A method of treating a disease , health condition or disorder in a subject , comprising administering a therapeutically effective amount of a compound depicted in Table I , or a pharmaceutically acceptable salt thereof , to the subject in need of the treatment , wherein the disease , health condition or disorder is selected from: disorders related to high blood pressure and decreased coronary blood flow; resistant hypertension; diabetic hypertension; congestive heart failure; diastolic or sistolic dysfunction; coronary insufficiency; arrhythmias;', 'thromboembolic disorders and ischemias; stable or unstable angina pectoris;', 'peripheral arterial disease, peripheral occlusive arterial disease;', 'pulmonary/respiratory conditions such as pulmonary hypertension, pulmonary arterial hypertension, and associated pulmonary vascular remodeling, pulmonary hypertonia, primary pulmonary hypertension, secondary pulmonary hypertension, familial pulmonary hypertension, sporadic pulmonary hypertension, pre-capillary pulmonary hypertension, idiopathic pulmonary hypertension, thrombotic pulmonary arteriopathy, plexogenic pulmonary arteriopathy;', 'pulmonary hypertension associated with or related to: left ventricular dysfunction, hypoxemia, mitral valve disease, constrictive pericarditis, aortic stenosis, cardiomyopathy, mediastinal fibrosis, pulmonary fibrosis, anomalous pulmonary venous drainage, pulmonary venooclusive disease, pulmonary vasculitis, collagen vascular disease, congenital heart disease, pulmonary venous hypertension, interstitial lung disease, sleep-disordered breathing, sleep apnea, alveolar hypoventilation disorders, chronic exposure to high altitude, neonatal lung disease, alveolar-capillary dysplasia, ...

sGC STIMULATORS

Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

TREATMENT OF CNS DISEASES WITH sGC STIMULATORS

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′,5′-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable. 2. A dosage form comprising the pharmaceutical composition of .4. The method of claim 3 , wherein the CNS disease is selected from Alzheimer's disease (AD) claim 3 , amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) claim 3 , Down's syndrome claim 3 , dementia claim 3 , vascular dementia (VD) claim 3 , vascular cognitive impairment claim 3 , Binswanger's dementia (subcortical arteriosclerotic encephalopathy) claim 3 , cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL or CADASIL syndrome) claim 3 , frontotemporal lobar degeneration or dementia claim 3 , HIV-associated dementia claim 3 , Lewy body dementia claim 3 , pre-senile dementia (mild cognitive impairment or MCI) claim 3 , glaucoma claim 3 , Huntington's disease (or Huntington's chorea claim 3 , HD) claim 3 , multiple sclerosis (MS) claim 3 , multiple system atrophy (MSA) claim 3 , Parkinson's disease (PD) claim 3 , Parkinsonism Plus claim 3 , spinocerebellar ataxias claim 3 , Steel-Richardson-Olszewski disease (progressive supranuclear palsy) claim 3 , attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD).5. The method of claim 4 , wherein the CNS disease is Alzheimer's disease.6. The method of claim 5 , wherein the mild to moderate Alzheimer's disease or moderate to severe Alzheimer's disease.7. The method of claim 4 , wherein the CNS disease is vascular dementia.8. The method of claim 4 , wherein the CNS disease is ...

SGC STIMULATORS

Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. 181.-. (canceled) This application is a division of U.S. patent application Ser. No. 15/435,723, filed Feb. 17, 2017; which is a continuation of U.S. patent application Ser. No. 14/264,200, filed Apr. 29, 2014; which is a division of U.S. patent application Ser. No. 13/174,676, filed Jun. 30, 2011 and now U.S. Pat. No. 8,748,442; which claims the benefit of priority from U.S. Provisional Application Nos. 61/360,236, filed Jun. 30, 2010; 61/406,845, filed Oct. 26, 2010; and 61/474,563, filed Apr. 12, 2011. The disclosures of each of the aforementioned patent applications are hereby incorporated by reference in their entireties.The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations thereof and their use, alone or in combination with one or more additional agents, for treating and/or preventing various diseases, wherein an increase in the concentration of nitric oxide (NO) might be desirable.Soluble guanylate cyclase (sGC) is the primary receptor for nitric oxide (NO) in vivo. sGC can be activated via both NO-dependent and NO-independent mechanisms. In response to this activation, sGC converts GTP into the secondary messenger cyclic GMP (cGMP). The increased level of cGMP, in turn, modulates the activity of downstream effectors including protein kinases, phosphodiesterases (PDEs), and ion channels.In the body, NO is synthesized from arginine and oxygen by various nitric oxide synthase (NOS) enzymes and by sequential reduction of inorganic nitrate. Three distinct isoforms of NOS have been identified: inducible NOS (iNOS or NOS II) found in activated macrophage cells; constitutive neuronal NOS (nNOS or NOS I), involved in neurotransmission and long term potentiation; and ...

sGC STIMULATORS

Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

2 - benzyl, 3 - (pyrimidin- 2 -yl) substituted pyrazoles useful as sgc stimulators

2-Benzyl, 3 - (pyrimidin- 2 -YL) substituted pyrazoles are described. They are useful as stimulators of sGC, particularly NO - independent, heme - dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

Sgc stimulators

Compounds of Formula (I) are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

Additives package and magnetorheological fluid formulations for extended durability

An additives package for use in an MR fluid formulation is provided, as well as an MR fluid formulation containing the additives package. In one embodiment, the additives package comprises an organomolybdenum dithiocarbamate, an ashless dithiocarbamate, and a triazole compound, such as a tolutriazole compound. In another embodiment, the additives package may further include an aminic antioxidant, such as an alkylated diphenylamine. In another embodiment, the additives package is free of an organomolybdate ester. In another embodiment, the additives package consists of the organomolybdenum dithiocarbamate, the ashless dithiocarbamate, the triazole compound, and optionally the aminic antioxidant. In addition to the additives package, the magnetorheological fluid formulation comprises magnetizable particles, a carrier fluid, and a thickening agent.

Increasing power efficiency of turbo mode operation in a processor

In one embodiment, a processor has multiple cores to execute threads. The processor further includes a power control logic to enable entry into a turbo mode based on a comparison between a threshold and value of a counter that stores a count of core power and performance combinations that identify turbo mode requests of at least one of the threads. In this way, turbo mode may be entered at a utilization level of the processor that provides for high power efficiency. Other embodiments are described and claimed.

Increasing power efficiency of turbo mode operation in a processor

In one embodiment, a processor has multiple cores to execute threads. The processor further includes a power control logic to enable entry into a turbo mode based on a comparison between a threshold and value of a counter that stores a count of core power and performance combinations that identify turbo mode requests of at least one of the threads. In this way, turbo mode may be entered at a utilization level of the processor that provides for high power efficiency. Other embodiments are described and claimed.

Increasing power efficiency of turbo mode operation in a processor

In one embodiment, a processor has multiple cores to execute threads. The processor further includes a power control logic to enable entry into a turbo mode based on a comparison between a threshold and value of a counter that stores a count of core power and performance combinations that identify turbo mode requests of at least one of the threads. In this way, turbo mode may be entered at a utilization level of the processor that provides for high power efficiency. Other embodiments are described and claimed.

sGC STIMULATORS

【課題】可溶性グアニル酸シクラーゼ（ｓＧＣ）を一酸化窒素（ＮＯ）非依存的に活性化する新規方法の提供。【解決手段】下式Ｉで表わされる化合物。（（ＪＣ）ｐ−環Ｃは置換可イソキサゾリル基等の置換可単環式５員ヘテロアリール基；（ＪＢ）ｎ−環Ｂは置換可フェニル基、フェニル、、１若しくは２個の環構成窒素原子を含有する置換可６員ヘテロアリール基、又はチエニル基；Ｘ１はＣＨ、Ｎ等；ＪＡはＨ、ハロゲン等；ＪＤはＨ、ハロゲン等；Ｎ（Ｒ１）Ｒ２は置換可アミノ基、置換可含窒素複素環基等。）【選択図】なし

Sgc stimulators

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, Formula (I) wherein ring D, ring A, ring E, JB, n, JD, J, X, Z, Z1, RC1, RC2, Y, R9, o and W are as defined herein.

System and method for microphone activation using visual speech cues

A system for activating a microphone based on visual speech cues, in accordance with the invention, includes a feature tracker coupled to an image acquisition device. The feature tracker tracks features in an image of a user. A region of interest extractor is coupled to the feature tracker. The region of interest extractor extracts a region of interest from the image of the user. A visual speech activity detector is coupled to the region of interest extractor and measures changes in the region of interest to determine if a visual speech cue has been generated by the user. A microphone is turned on by the visual speech activity detector when a visual speech cue has been determined by the visual speech activity detector. Methods for activating a microphone based on visual speech cues are also included.

Phosphorus prodrugs of sGC stimulators

The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof, wherein J

Inhibitors of diacylglycerol O-acylotransferase type 1 enzyme

Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Pharmaceutical compositions of formula (I) and related methods for treating or preventing metabolic diseases or conditions.

SGC stimulators

El compuesto representado por la siguiente fórmula, o una sal farmacéuticamente aceptable del mismo: **(Ver fórmula)** The compound represented by the following formula, or a pharmaceutically acceptable salt thereof: ** (See formula) **

Process for the preparation of easily dispersible, high color strength, powdered alkali blue pigments

PROCESS FOR THE PREPARATION OF EASILY DISPERSIBLE HIGH COLOR STRENGTH, POWDERED ALKALI BLUE PIGMENTS Abstract of the Disclosure .... . _ Easily dispersible alkali blue pigments with high color strength are obtained if the pigment is precipitated in the presence of (1) primary, secondary or tertiary aliphatic amines, (2) N-alkylamino alkanic acid, (3) a diaryl or triarylamine, (4) an acid or neutral aliphatic ester of phosphoric acid, (5) a half ester of sulfuric acid based on fatty alcohol, fatty alcohol-EO adducts or alkyl phenol-EO adducts, (6) an alkane or alkene sulfonic acid on a dialkylsulfimide, (7) EO adducts based on alkylphenols, alkanols or alkylamines, (8) polypropylene glycol or PO/EO block copolymers based on alkane diols or alkane polyols or in the presence of mixtures of these compounds or is mixed with at least one of the substances listed under (1) to (8) after the precipitation with acid in the acid suspension and is isolated. Alkali blue pigments are obtained which are easily dispersible in offset printing ink varnishes and which result in excellent color strength of the printed matter.

Sgc stimulators

Compounds of Formula (I) are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme.

La presente invención se refiere a compuestos de la fórmula (I): en donde Q, G1, G2 y G3, son como aquí se definen. También se describen composiciones farmacéuticas y métodos para el tratamiento de las enfermedades o padecimientos relacionados con la enzima DGAT-1.

Dragline rotating frame structure

A frame for an excavating machine having a ring gear wherein the frame is rotated with respect to the ring gear includes top and bottom plates. A plurality of compartments are circularly disposed within the frame and between the plates. A plurality of drive units are provided wherein each drive unit is mounted within one of the plurality of compartments below the top plate. The drive units extend below the bottom plate for driving engagement with the ring gear. A plurality of radially disposed bulkheads are located within the frame between the top and bottom plates and between the plurality of compartments.

Increasing power efficiency of turbo mode operation in a processor

In one embodiment, a processor has multiple cores to execute threads. The processor further includes a power control logic to enable entry into a turbo mode based on a comparison between a threshold and value of a counter that stores a count of core power and performance combinations that identify turbo mode requests of at least one of the threads. In this way, turbo mode may be entered at a utilization level of the processor that provides for high power efficiency. Other embodiments are described and claimed.

Sgc stimulators

Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme

Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Pharmaceutical compositions of formula (I) and related methods for treating or preventing metabolic diseases or conditions.

Pyrazole derivatives as sgc stimulators

There are described imidazole and pyrazole derivatives which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Diacylglycerol O-acyltransferase type 1 enzyme inhibitors

Un compuesto que tiene la fórmula (I), o una sal farmacéuticamente aceptable del mismo donde Q es fenilo o un heteroarilo monocíclico, opcionalmente sustituido con 1, 2 o 3 sustituyentes como se representan por T, donde cada T es independientemente alquilo, alquenilo, alquinilo, halógeno, -CN, -NO2, -OR1, -C) C (O) (R2), -N (Rw) (R1), -N (Rw) C (O) (R1), -N (Rw) -C (O) O (R1), -N (Rw) -C (O) N (R1) 2, -N (Rw) -S (O) 2 (R2), -C (O) O (R1), C (O) N (Rw) (R1), -CCO) R1, -SR1, -S (O) R2, -S (O) 2R2, -S (O) 2N (Rw) (R1), - (CRgRh) t-CN, - (CRgRh) t-NO2, - (CRgRh) t-OR1, - (CRgRh) t-OC (O) (R2) s - (CRgRh) t-N (Rw) (R1), - (CRgRh) t-N (Rw) C (O) (R1), - (CRgRh) t-N (Rw) -C (O) O (R1), - (CRgRh) tN (Rw) -C (O) N (R1) 2, - (CRgRh) t-N (Rw) -S (O) 2 (R2), - (CRgRh) t-C (O) O (R1), - (CRgRh) t-C (O) N (Rw) (R1), - (CRgRh) t-C (O) R1, (CRgRh) t-SR1, - (CRgRh) t-S (O) R2, - (CRgRh) t-S (O) 2R2, - (CRgRh) t-S (O) 2N (Rw) (R1) o haloalquilo; como alternativa, dos de los sustituyentes T adyacentes, junto con los átomos de carbono a los que están unidos, forman un anillo monocíclico seleccionados entre el grupo que consiste en fenilo, heterociclo y heteroarilo, donde opcionalmente cada anillo está opcionalmente sustituido adicionalmente con 1, 2 o 3 sustituyentes seleccionados entre el grupo que consiste en oxo, alquilo, alquenilo, alquinilo, halógeno, -CN, -NO2, -OR1-OC (O) (R2), -N (Rw) (R1), N (Rw) C (O) (R1), -N (Rw) -C (O) O (R1), -N (Rw) -C (O) N (R1) 2, -N (Rw) -S (O) 2 (R2), -C (O) O (R1), -C (O) N (Rw) (R1), -C (O) R1, -SR1, -S (O) R2, -S (O) 2R2, -S (O) 2N (Rw) (R1), - (CRgRh) t-CN, - (CRgRh) t-NO2, - (CRgRh) t-OR1, - (CRgRh) -OC (O) (R2), (CRgRh) t-N (Rw) (R1), - (CRgRh) t-N (RwC (O) (R1), - (CRgRh) t-N (Rw) -C (O) O (R1), - (CRgRh) t-N (Rw) -C (O) N (R1) 2, - (CRgRh) tN (Rw) -S (O) 2 (R2), - (CRgRh) t-C (O) O (R1), - (CRgRh) t-C (O) N (Rw) (R1), - (CRgRh) t-C (O) R1, - (CRgRh) t-SR1, - (CRgRh) tS (O) R2, - (CRgRh) t-S (O) 2R2, - (CRgRh) t-S (O) 2N (Rw) (R1) y ...

Fused bicyclic sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: G:---Z (JC) X y-:--X (R10)q -JN W J B (j B)n Formula I. 18602866_1 (GHMatters) P110713.AU.1

Sgc stimulators

Compounds of Formula (I) are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme

INHIBITORS OF DIACYLGLYCEROL o-ACYLTRANSFERASE TYPE 1 ENZYMEAbstractCompounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof, Pharmaceutical compositions of formula (I) and related methods of treating or preventing metabolic diseases or conditions. Formula (I)

Modulators of trpml, their compositions and methods of use

The present disclosure relates to methods of treating a ciliopathy, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound or pharmaceutical composition thereof, wherein the compound modulates a TRPML ion channel. The disclosure also relates to pharmaceutical compounds of Formula (III) and subformulas thereof, or a pharmaceutically acceptable salt or composition thereof, and methods of their use for modulating TRPML ion channels, and for treating disorders.

Phosphorus prodrugs of sgc stimulators

The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof, wherein JB, n, R1, R2, R3, R4, R5, m and X as defined herein.

Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme

Disclosed herein are compounds of formula (I), wherein G1 is phenyl or pyridinyl, and the other substituents are as defined within the specification, processes for its preparation and uses thereof. Said compounds are useful as inhibitors of diacylglycerol O-acyltransferase type 1 (DGAT-1) enzyme and are therefore useful in the treatment of diseases related thereof, such as type 2 diabetes, obesity, elevated plasma triglycerides, metabolic syndrome, non-alcoholic steatohepatitis, and non-alcoholic fatty liver disease.

SGC stimulators

Un compuesto representado por la siguiente fórmula estructural: **(Ver fórmula)** o una sal farmacéuticamente aceptable del mismo. A compound represented by the following structural formula: **(See formula)** or a pharmaceutically acceptable salt thereof.

Increasing power efficiency of turbo mode operation in a processor

In one embodiment, a processor has multiple cores to execute threads. The processor further includes a power control logic to enable entry into a turbo mode based on a comparison between a threshold and value of a counter that stores a count of core power and performance combinations that identify turbo mode requests of at least one of the threads. In this way, turbo mode may be entered at a utilization level of the processor that provides for high power efficiency. Other embodiments are described and claimed.

Inhibitors of Diacylglycerol O-acyltransferase Type 1 Enzyme

The present invention relates to compounds of formula (I): wherein Q, G 1 , G 2 , and G 3 , are defined herein. Pharmaceutical compositions and methods for treating DGAT- 1 related diseases or conditions are also disclosed.

Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme

Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Pharmaceutical compositions of formula (I) and related methods for treating or preventing metabolic diseases or conditions.

Process for the preparation of easily dispersible, high color strength, powdered alkali blue pigments

Easily dispersible alkali blue pigments with high color strength are obtained if the pigment is precipitated in the presence of (1) primary, secondary or tertiary aliphatic amines, (2) N-alkylamino alkanic acid, (3) a diaryl or triarylamine, (4) an acid or neutral aliphatic ester of phosphoric acid, (5) a half ester of sulfuric acid based on fatty alcohol, fatty alcohol-EO adducts or alkyl phenol-EO adducts, (6) an alkane or alkene sulfonic acid on a dialkylsulfimide, (7) EO adducts based on alkylphenols, alkanols or alkylamines, (8) polypropylene glycol or PO/EO block copolymers based on alkane diols or alkane polyols or in the presence of mixtures of these compounds or is mixed with at least one of the substances listed under (1) to (8) after the precipitation with acid in the acid suspension and is isolated. Alkali blue pigments are obtained which are easily dispersible in offset printing ink varnishes and which result in excellent color strength of the printed matter.

Platform independent isa emulator as middleware

compound, pharmaceutical composition, and method of treating a disease, health condition or disorder

1 / 1 resumo “composto, composiã‡ãƒo farmacãšutica, e, mã‰todo de tratamento de uma doenã‡a, condiã‡ãƒo de saãšde ou distãšrbio ” sã£o descritos compostos das fã³rmulas i' e i que sã£o ãºteis como estimulantes de sgc, particularmente estimulantes independentes de no e dependentes de heme. esses compostos tambã©m sã£o ãºteis para o tratamento, prevenã§ã£o ou manutenã§ã£o de diversos distãºrbios que sã£o divulgados neste documento. fã³rmula i’ fã³rmula i 1 / 1 abstract “compound, pharmaceutical composition, and method of treating a disease, health condition or disorder†are Compounds of formulas i' and i are described which are useful as sgc stimulants, particularly non-independent and heme-dependent stimulants. these compounds are also useful for the treatment, prevention or maintenance of various disorders which are disclosed herein. fan³rmula i' fan³rmula i

Efficient frequency boost operation

Systems and methods of operating a computing system may involve identifying a plurality of state values, wherein each state value corresponds to a computing thread associated with a processor. An average value can be determined for the plurality of state values, wherein a determination may be made as to whether to grant a frequency boost request based at least in part on the average value.

Efficient frequency boost operation

Systems and methods of operating a computing system may involve identifying a plurality of state values, wherein each state value corresponds to a computing thread associated with a processor. An average value can be determined for the plurality of state values, wherein a determination may be made as to whether to grant a frequency boost request based at least in part on the average value.

2-benzyl,3(pyrimidin-2-yl)substituted pyrazoles useful as sgc stimulators

2-Benzyl, 3 - (pyrimidin- 2 -YL) substituted pyrazoles are described. They are useful as stimulators of sGC, particularly NO - independent, heme - dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed.

Apparatus, method and system for increasing power efficiency of turbo mode operation in a processor

在一實施例中，處理器具有多核心以執行線程。該處理器進一步包括電力控制邏輯以依據閾值與儲存核心電力計數及識別至少一該線程之渦輪加速模式要求之執行組合的計數器值之間比較，使進入渦輪加速模式。如此一來，可以提供用於高電源效率之該處理器的利用位準進入渦輪加速模式。亦說明及主張其他實施例。

Inhibitors of diacylglycerol o-acylotransferase type 1 enzyme.

Compuestos de la fórmula (I) (ver fórmula (I)) o una sal, profármaco, sal de profármaco o una combinación de ellas, aceptables para uso farmacéutico. Composiciones farmacéuticas de la fórmula (I) y métodos relacionados para tratar o prevenir enfermedades o condiciones metabólicas.

Identification of the distinction between the beginning of a new write back cycle and an ongoing write cycle

A computer system includes a microprocessor having an internal cache memory and control unit that performs write-back operations to external memory responsive to an external signal indicating that a valid external address has been driven onto the address pins of the microprocessor. Under control of a state machine control, a unit within the microprocessor provides an indication signal to the external component that a current write cycle is a write-back cycle; this enables the system to distinguish between an ongoing write cycle generated by the processor, and a new write-back cycle. An additional signal is generated by the microprocessor in the event that the external address indicates a cache hit to a modified line.

Stabilization of magnetorheological fluid suspensions using a mixture of organoclays

sGC STIMULATORS

Compounds of Formulae I′ and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Inhibitors of diacylglycerol O-acylotransferase type 1 enzyme

INHIBITORS OF DIACYLGLYCEROL O-ACYLOTRANSFERASE TYPE I Compounds of formula (I), or a pharmaceutically acceptable salt, prodrug, salt of a prodrug, or a combination thereof. Pharmaceutical compositions of formula (I) and related methods for treating or preventing metabolic diseases or conditions.

sGC Stimulators

Abstract Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. j (Jc)p N (JB R. N ,1(JB)N N D \ 2 X2- (JD) jA jD Formula I' Formula I

Fused bicyclic sgc stimulators.

La presente invención se relaciona con estimuladores de la guanilato ciclasa soluble (sGC), formulaciones farmacéuticas que los comprenden y sus usos, sólo o en combinación con uno o más agentes adicionales, para el tratamiento de varias enfermedades, en donde sea conveniente un aumento de la concentración de óxido nítrico (NO) y/o un aumento de la concentración de monofosfato de guanosina cíclico (cGMP), o una regulación positiva de la vía de NO. Los compuestos son de Fórmula I: (ver Fórmula).

Sgc stimulators

Compounds of Formulae (I') and (I) are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed.

Resource sharing to reduce implementation costs in a multicore processor

A processor may include several processor cores, each including a respective higher-level cache; a lower-level cache including several tag units each including several controllers, where each controller corresponds to a respective cache bank configured to store data, and where the controllers are concurrently operable to access their respective cache banks; and an interconnect network configured to convey data between the cores and the lower-level cache. The controllers in a given tag unit may share access to a resource that may include one or more of an interconnect egress port coupled to the interconnect network, an interconnect ingress port coupled to the interconnect network, a test controller, or a data storage structure.

SGC STIMULATORS

Se describen compuestos de Fórmula I. Los mismos son útiles como estimuladores de sGC, en particular estimuladores independientes de NO y dependientes de hemo. Estos compuestos pueden ser útiles para tratar, prevenir o manejar distintos trastornos que se divulgan en el presente.

Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme

The present invention relates to compounds of formula (I) wherein R1, R3, X, Q, Z, A, D, m, and n are defined herein. Pharmaceutical compositions and methods for treating DGAT-1 related diseases or conditions are also disclosed.

Sgc stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I).

Surface treated alkali blue pigment

A soft textured high strength Alkali Blue pigment is produced by treating an aqueous dispersion of the pigment from a regular, untreated presscake with an aqueous solution of a tertiary amine acetate followed by the addition of ammonium hydroxide. Alternatively, the pigment dispersion is treated with an aqueous emulsion/dispersion of a tertiary amine. The mixture is then filtered and dried.

Sgc stimulators

Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc).

La presente solicitud de patente describe los compuestos de acuerdo con la Fórmula (I) mostrados más abajo, o sales farmacéuticamente aceptables de estos, en donde JB, n, R1, R2, R3, R4, R5, m y X se definen en la presente descripción. (ver Fórmula).

Phosphorus prodrugs of sGC stimulators

The present patent application discloses the compounds according to Formula I shown below, or pharmaceutically acceptable salts thereof, wherein JB, n, R, R 2, R 3, R4 , Rim and X as defined herein. ___(JB)n N N 'N N R 4 R4 -(CH 20)m-X N N R2 R3 Formula I

Phosphorus prodrugs of sgc stimulators

Estimulantes de sgc

estimulantes de sgc. a presente descrição refere-se a estimulantes de guanilato ciclase solúvel (sgc), a sais farmaceuticamente aceitáveis destes e a formulações farmacêuticas os compreendendo e a seus usos, separadamente ou em combinação com um ou mais agentes adicionais, para o tratamento de várias doenças, onde um aumento na concentração de óxido nítrico (no) e/ou um aumento na concentração de guanosina monofosfato (cgmp), ou ambos, ou uma suprarregulação da rota de no é desejável. em algumas realizações, os compostos são aqueles da tabela i ou um sal farmaceuticamente aceitável dos mesmos.

Sgc stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an uregulation of the NO pathway is desirable. In some embodiments, the compounds are those of Table I or a pharmaceutically acceptable salt thereof.

Fused bicyclic sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: G:---Z (JC) X y-:--X (R10)q -JN W J B (j B)n Formula I. 18602866_1 (GHMatters) P110713.AU.1

Treatment of cns diseases with sgc stimulators

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3',5'-monophosphate (cGMP) or both, or an upregulation of the NO-sGC-cGMP pathway is desirable. Compounds useful in the methods of the invention are those of Formula (I) or pharmaceutically acceptable salts thereof.

Treatment of cns diseases with sgc stimulators

Sgc stimulators

Co-polymer soil subgrade binders

This invention is in the field of road construction as it relates to improving the quality and lifetime of asphalt roads and pavement surfaces. The invention relates to methods and compositions utilizing co-polymers in combination with soil to form improved subgrade soil binder compositions for supporting asphalt roads and pavement surfaces.

TREATMENT OF CNS DISEASES WITH sGC STIMULATORS

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3′,5′-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.